Brief: Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control

MetaVia

18/03/2026 12:04

March 18 (Reuters) - MetaVia Inc MTVA.O:

METAVIA ADVANCES GLP-1-BASED OBESITY PROGRAM WITH IRB APPROVAL FOR HIGHER-DOSE PHASE 1 STUDIES OF DA-1726, A GLP-1 AND GLUCAGON DUAL AGONIST DEMONSTRATING BEST-IN-CLASS POTENTIAL FOR WEIGHT LOSS AND GLUCOSE CONTROL

Source text: ID:nPn73Ftjda

Further company coverage: MTVA.O

 ((Reuters.Briefs@thomsonreuters.com;))